# GT Medical Technologies Closes Oversubscribed $100 Million Series E to Advance GammaTile Brain Tumor Implant

> financing · REPORTED · 2026-06-09

On June 9, 2026, GT Medical Technologies closed an oversubscribed $100 million Series E round led by Viking Global Investors to commercialize GammaTile, an FDA-cleared bioresorbable radiotherapy implant placed in the brain tumor cavity at surgery. The raise follows ROADS trial data presented at ASCO 2026 showing GammaTile reduced tumor recurrence risk by 93% and death risk by 41% at 12 months versus standard care.

- Company: GT Medical Technologies
- Sector: medical devices
- Primary source: https://www.prnewswire.com/news-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors-302794352.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.